← Back to Analyst Consensus 
SGRY Buy
Surgery Partners, Inc.
Current Price —
Implied Upside —
Analysts 18
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 1 reiterations from 1 firms
Next Earnings
Nov 10, 2026 (14 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Sep 30, 2026 | RBC Capital | reiterate | Outperform → Outperform | — | 55% |
| Sep 18, 2026 | TD Cowen | reiterate | Buy → Buy | — | 54% |
| Sep 14, 2026 | JP Morgan | maintain | Neutral → Neutral | — | 55% |
| Aug 11, 2026 | TD Cowen | maintain | Buy → Buy | — | 54% |
| Aug 11, 2026 | RBC Capital | maintain | Outperform → Outperform | — | 55% |
| Aug 11, 2026 | Cantor Fitzgerald | reiterate | Overweight → Overweight | — | 50% |
| Mar 5, 2026 | TD Cowen | maintain | Buy → Buy | — | 54% |
| Mar 5, 2026 | UBS | maintain | Buy → Buy | — | 54% |
| Mar 5, 2026 | Mizuho | maintain | Outperform → Outperform | — | 52% |
| Mar 4, 2026 | RBC Capital | maintain | Outperform → Outperform | — | 55% |
| Mar 3, 2026 | Barclays | maintain | Equal-Weight → Equal-Weight | — | 53% |
| Dec 18, 2025 | Mizuho | maintain | Outperform → Outperform | $19 | 52% |
| Nov 24, 2025 | JP Morgan | maintain | Neutral → Neutral | $20 | 55% |
| Nov 21, 2025 | Barclays | maintain | Equal-Weight → Equal-Weight | $18 | 53% |
| Nov 17, 2025 | Mizuho | maintain | Outperform → Outperform | $22 | 52% |
| Nov 13, 2025 | UBS | maintain | Buy → Buy | $29 | 54% |
| Nov 11, 2025 | RBC Capital | maintain | Outperform → Outperform | $31 | 55% |
| Nov 11, 2025 | Benchmark | maintain | Buy → Buy | $30 | 54% |
| Oct 7, 2025 | Cantor Fitzgerald | reiterate | Overweight → Overweight | $36 | 50% |
| May 27, 2025 | Barclays | maintain | Equal-Weight → Equal-Weight | $24 | 53% |
| Apr 21, 2025 | Benchmark | reiterate | Buy → Buy | $35 | 54% |
| Mar 25, 2025 | RBC Capital | reiterate | Outperform → Outperform | $35 | 55% |
| Mar 11, 2025 | Macquarie | maintain | Outperform → Outperform | $33 | 56% |
| Dec 3, 2024 | JP Morgan | maintain | Neutral → Neutral | $28 | 55% |
| Nov 20, 2024 | RBC Capital | maintain | Outperform → Outperform | $35 | 55% |
| Nov 19, 2024 | Macquarie | maintain | Outperform → Outperform | $34 | 56% |
| Nov 13, 2024 | Macquarie | maintain | Outperform → Outperform | $34 | 56% |
| Nov 4, 2024 | Macquarie | maintain | Outperform → Outperform | $35 | 56% |
| Oct 14, 2024 | UBS | initiate | — → Buy | $38 | 54% |
| Oct 11, 2024 | Keybanc | initiate | — → Sector Weight | $0 | 52% |
| Oct 4, 2024 | Cantor Fitzgerald | reiterate | Overweight → Overweight | $43 | 50% |
| Aug 26, 2024 | Benchmark | reiterate | Buy → Buy | $50 | 54% |
| Aug 20, 2024 | Cantor Fitzgerald | reiterate | Overweight → Overweight | $43 | 50% |
| Aug 19, 2024 | Cantor Fitzgerald | reiterate | Overweight → Overweight | $43 | 50% |
| Aug 7, 2024 | Citigroup | maintain | Buy → Buy | $36 | 54% |
| Aug 7, 2024 | Benchmark | reiterate | Buy → Buy | $50 | 54% |
| Aug 7, 2024 | RBC Capital | reiterate | Outperform → Outperform | $49 | 55% |
| Jul 10, 2024 | Cantor Fitzgerald | reiterate | Overweight → Overweight | $43 | 50% |
| Jul 9, 2024 | Cantor Fitzgerald | reiterate | Overweight → Overweight | $43 | 50% |
| Jul 2, 2024 | Cantor Fitzgerald | reiterate | Overweight → Overweight | $43 | 50% |
| Jun 28, 2024 | Macquarie | initiate | — → Outperform | $31 | 56% |
| May 8, 2024 | Citigroup | maintain | Buy → Buy | $38 | 54% |
| May 1, 2024 | Benchmark | reiterate | Buy → Buy | $50 | 54% |
| Apr 10, 2024 | Cantor Fitzgerald | reiterate | Overweight → Overweight | $43 | 50% |
| Mar 6, 2024 | Barclays | initiate | — → Equal-Weight | $35 | 53% |
| Mar 5, 2024 | Cantor Fitzgerald | reiterate | Overweight → Overweight | $43 | 50% |
| Feb 29, 2024 | RBC Capital | reiterate | Outperform → Outperform | $49 | 55% |
| Feb 27, 2024 | Citigroup | maintain | Buy → Buy | $42 | 54% |
| Feb 27, 2024 | Cantor Fitzgerald | maintain | Overweight → Overweight | $43 | 50% |
| Nov 14, 2023 | TD Cowen | upgrade | Market Perform → Outperform | $35 | 54% |
Price Target Trend
Apr 17, 2026 Oct 26, 2026
EPS Estimates
0y —
0q —
+1y —
+1q —
Cross-Platform Signals
No cross-platform signals in the last 90 days